End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.29 CNY | -1.93% | +0.66% | -10.26% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.26% | 1.18B | - | ||
-14.35% | 77.13B | B+ | ||
+14.09% | 8.4B | B- | ||
+27.62% | 3.79B | B- | ||
-0.70% | 3.22B | B- | ||
+14.70% | 1.64B | - | ||
-10.12% | 1.5B | B | ||
-22.60% | 1.3B | C- | ||
-4.20% | 1.25B | - | ||
+5.06% | 1.1B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688526 Stock
- Ratings Wuhan Keqian Biology Co.,Ltd